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a b s t r a c t
The UL4 gene is conserved within the genome of defective interfering particles of equine herpesvirus
type 1 (EHV-1) that mediate persistent infection. Here, we show that the UL4 protein inhibits EHV-1
reporter gene expression by decreasing the level of transcribed mRNA. The UL4 protein did not bind any
gene class of EHV-1 promoters in electromobility or chromatin immunoprecipitation assays, but directly
interacted with the TATA box-binding protein (TBP) and the carboxy-terminal domain of RNA
polymerase II both in vitro (GST-pulldown assays) and in infected cells (coimmunoprecipitation
analyses). Microarray analyses of the expression of the 78 EHV-1 genes revealed that viral late genes
important for virion assembly displayed enhanced expression in cells infected with UL4-null virus as
compared to wild-type or UL4-restored EHV-1. Quantitative PCR analyses showed that viral DNA
replication was not retarded in cells infected with the UL4-null virus as compared to wild-type EHV-1.
& 2013 Elsevier Inc. All rights reserved.
Introduction
The Alphaherpesvirinae subfamily member equine herpesvirus
1 (EHV-1) is a signiﬁcant etiologic agent of severe respiratory,
neurological, and abortigenic disease in equines worldwide (Allen
and Bryans, 1986; O’Callaghan and Osterrieder, 2008). The viral
gene program is expressed in a coordinated and temporal fashion,
such that the 78 EHV-1 genes (Telford et al., 1992) are expressed at
immediate-early (IE), early (E), and late (L) stages of infection
(Caughman et al., 1985; Gray et al., 1987). Extensive work has been
completed to describe the EHV-1 proteins responsible for control-
ling the expression of viral genes. The majority of the regulatory
proteins are activators of viral gene expression. The essential
IE gene encodes the sole IE protein (IEP) that is the major
trans-activator of early and some late genes (Buczynski et al.,
1999; Caughman et al., 1988; Garko-Buczynski et al., 1998; Grundy
et al., 1989; Smith et al., 1992, 1994). The IEP also functions to
trans-repress its own gene expression (Smith et al., 1992). Early
regulatory proteins IR4P and UL5P function in a synergistic
manner with the IEP to mediate the full activation of early and
late EHV-1 gene promoters (Albrecht et al., 2004; Holden et al.,
1995; Kim et al., 1997; Zhao et al., 1995). The powerful and
promiscuous EICP0P can independently activate expression of all
three gene classes and is capable of antagonizing the trans-
activation potential of the IEP (Bowles et al., 1997, 2000). The late
equine α-trans-inducing factor (ETIF) is a tegument protein
required for secondary envelopment and virus egress as well as
the activation of expression of the IE gene promoter (Kim and
O’Callaghan, 2001; Lewis et al., 1993; Purewal et al., 1994; von
Einem et al., 2006). The early IR2 protein and the IR3 transcript
serve to inhibit EHV-1 gene expression (Ahn et al., 2010; Kim et al.,
2006, 2011). The IR2P is a major inhibitory protein and is a
truncated version of the IEP (Harty and O’Callaghan, 1991; Kim
et al., 2006, 2011). Finally, the IR3 gene is unique to EHV-1 (Holden
et al., 1992), lies antisense to the IE transcript, does not produce a
translated protein, and plays a role in down-regulating IE gene
expression (Ahn et al., 2007, 2010).
Serial, high multiplicity passage of EHV-1 in cell culture or
Syrian hamsters results in the production of defective interfering
particles (DIP) that are capable of interfering with standard viral
replication and establishing a state of persistent infection
(Campbell et al., 1976; Chen et al., 1996, 1999; Dauenhauer et al.,
1982; Ebner et al., 2008; Ebner and O’Callaghan, 2006; Henry
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et al., 1979). The DIP genome (7.5 kbp) is a severely truncated
and rearranged form of the standard viral genome (155 kbp) and
consists of only three genes: the perfectly conserved UL3 and UL4
genes and a hybrid gene that is comprised of portions of the IR4
and UL5 regulatory genes, which is important for the interference
with standard viral replication (Chen et al., 1996, 1999; Ebner
et al., 2008; Ebner and O’Callaghan, 2006). Until recently, no
functional role for the UL3 and UL4 proteins had been described.
It was reported that the UL4 protein was capable of inhibiting gene
expression in transient transfection assays, and cells infected with
EHV-1 lacking expression of the UL4 protein exhibited increased
levels of viral gene transcripts during lytic infection (Charvat et al.,
2011). Additionally, an EHV-1 lacking the complete UL4 open-
reading frame (ORF) was incapable of producing the DIP genome
after serial, undiluted passage, while a mutant EHV-1 that
possessed the UL4 ORF but did not express the UL4 protein was
still capable of generating the DIP genome (Charvat et al., 2012). In
the present study, we elaborate on the properties of the UL4
protein and begin to characterize its mechanism of inhibition.
Expression of the UL4 protein decreased reporter gene transcript
levels, possibly through direct interactions with the TATA box-
binding protein (TBP) and the carboxy-terminal domain of RNA
polymerase II. The UL4 protein is not a DNA-binding protein as it
fails to interact with EHV-1 promoters in gel shift assays and does
not associate with EHV-1 promoters in chromatin immunopreci-
pitation assays. Microarray analysis of the expression of all 78
EHV-1 genes in cells infected with wild-type or ΔUL4 EHV-1
revealed that late gene expression is enhanced in the absence of
the UL4 gene. Quantitative PCR analyses showed that viral DNA
synthesis was not retarded in cells infected with ΔUL4 EHV-1 as
compared to cells infected with wild type EHV-1.
Results
Expression of the UL4P decreases messenger RNA levels
In our previous publication (Charvat et al., 2011), we demon-
strated that the UL4 protein was capable of inhibiting luciferase
gene expression driven by various EHV-1 promoters, and experi-
ments using the chloramphenicol acetyltransferase (CAT) reporter
system validated these original ﬁndings (data not shown). Pre-
vious data indicated that the absence of UL4 protein synthesis
during infection with a mutant UL4 EHV-1 resulted in elevated
levels of viral transcripts (Charvat et al., 2011). These data
suggested that the UL4P may be responsible for affecting mRNA
levels; speciﬁcally, it may play a role in reducing transcripts. To
assess whether expression of the UL4 protein reduces transcript
levels, two groups of RK13 cells were transiently transfected with
the gK-Luc reporter plasmid, along with expression plasmids for
the EICP0 and UL4 proteins. The EICP0 protein has been shown to
activate the gK promoter (Bowles et al., 1997; Kim et al., 1999);
thus, it serves as a positive control for a protein that increases gene
expression. One group of transfected cells was used to determine
mRNA levels by harvesting RNA at 4 h post-transfection (hpt) and
performing a northern blot for the luciferase transcript (Fig. 1). The
other group of cells was used to perform a luciferase assay (48 hpt)
to correlate mRNA levels with luciferase activity (Fig. 1A). As
expected, expression of the EICP0 protein increased the luciferase
activity driven by the gK promoter, which was approximately two-
fold greater than gK-Luc activity alone. Additionally, the increase
in luciferase activity corresponded to a 78% increase in mRNA
levels (Fig. 1B). Conversely, expression of the UL4 protein
decreased the amount of luciferase activity by 50%, which coin-
cided with diminished amounts of the luciferase transcript which
were approximately 46% of the levels of the gK-Luc transcript
alone. Thus, the decreased luciferase activity correlated to
decreased mRNA levels. These ﬁndings indicate that inhibition of
gene expression by the UL4 protein is mediated at the level of
transcription.
Decreased transcript levels are not a result of mRNA instability
After observing that the gK-Luc transcript was decreased in the
presence of the UL4 protein, we examined mRNA stability as an
explanation for reduced transcript levels. It is possible that the UL4
protein plays a role in increasing mRNA turnover or decreasing the
stability of transcripts. To assess whether the UL4 protein was
involved in mRNA stability, we utilized quantitative real-time PCR
(qRT-PCR) to examine the half-life of mRNA from cells infected
with either wild-type or ΔUL4 EHV-1. Rabbit kidney RK13 cells
were infected at a multiplicity of 5 with each virus and incubated
for 12 h in normal medium. After 12 h of infection, the medium
was replaced with medium supplemented with 1 μM Actinomycin
D (Act D) to prevent any further transcription. RNA samples were
collected every 3 h for a total of 18 h and the levels of the late
glycoprotein 2 (gp2) transcript were determined by qRT-PCR. The
results are summarized in Table 1 and revealed that the overall
levels of the gp2 transcript are not greatly altered during the
course of the Act D treatment, suggesting that the gp2 mRNA is
inherently stable. Furthermore, the presence of the UL4 protein
had no effect on the stability of the gp2 mRNA as indicated by
similar levels of message at both 3 and 18 h post-Act D treatment.
These observations were reproducible in multiple experiments
and revealed that the UL4 protein is not responsible for increasing
mRNA instability and turnover, but rather it is likely involved in
the process of gene transcription.
The UL4 protein is not a DNA-binding protein
After observing that the expression of the UL4 protein inhibited
transient gene expression in reporter assays as well as decreased
the levels of viral transcripts, a mechanism to explain this
inhibitory activity was investigated. One possible mechanism is
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Fig. 1. Luciferase assay and northern blot analysis correlated the activity of the reporter
gene to the levels of luciferase gene transcripts. RK13 cells were transfected with the
gK-Luc reporter plasmid alone or in conjunction with either the EICP0 protein or UL4
protein expression plasmid. Transfection efﬁciency was routinely 80%. (A) Luciferase
activity was measured at 48 h post-transfection while (B) luciferase transcript levels
were examined by northern blot analysis 4 h post-transfection. Densitometry was used
to determine the percent mRNA levels. Results were reproducible in three independent
experiments. RLU, Relative Luminescence Units.
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that the UL4P binds to DNA in such a way to block transcription
from the targeted genes. This potential DNA-binding activity could
affect the assembly of the pre-initiation complex (PIC) involved in
the transcription of viral genes, as is observed with the EHV-1 IR2
protein (Kim et al., 2006, 2011) and the IE2 (IE86) protein of
human cytomegalovirus (Lee et al., 1996; Wu et al., 1993). Inhibi-
tion of viral transcription through DNA binding is also documented
for human papillomaviruses, where the E1M\widehatE2C fusion
protein inhibits viral gene expression as an E2-binding site-
speciﬁc repressor (Chiang et al., 1991). Therefore, the ability of
the UL4 protein to bind DNA was explored. Electromobility shift
assays (EMSA) were utilized to determine whether a recombinant
GST–UL4 fusion protein possessed DNA-binding activity for the IE,
TK, IR4, and UL5 gene promoters, all of which were shown to be
inhibited by the UL4P in reporter assays (Charvat et al., 2011;
unpublished observation). The GST protein alone was used as a
negative control; while the GST–IR2 fusion protein that has
documented DNA-binding properties (Kim et al., 1995) was used
as a positive control. As expected, the GST protein was unable to
bind any of the four radiolabeled promoters (Fig. 2, lanes A1, B1,
C1, and D1). In contrast, the GST–IR2 fusion protein readily bound
to the four EHV-1 promoters (Fig. 2, lanes A2, B2, C2, and D2),
which was conﬁrmed by a shift in the mobility of the radiolabeled
DNA–protein complexes using anti-IR2P monoclonal antibody A1.4
(Fig. 2, lanes A4, B3, C3, and D3). As expected, pre-immune serum
(Fig. 2, lane 3) or antibody to the EHV-1 TAD (Fig. 2, lanes A5 and
B4) failed to cause a supershift in the DNA–protein complexes.
However, no DNA-binding activity was observed for the GST–UL4
fusion protein with the IE, TK, IR4, or UL5 promoters over a range
of protein concentrations (Fig. 2, lanes A6–A8, B5–B7, C4–C6, and
D4–D6). Very minor bands were not reproducibly detected and
were considered as background.
To conﬁrm that the UL4 protein is not a DNA-binding protein,
chromatin immunoprecipitation (ChIP) assays were carried out.
EHV-1-infected HeLa cells were crosslinked with 1% formalde-
hyde, cell pellets were lyzed, and lysates were treated with
micrococcal nuclease. Immunoprecipitation was performed over-
night in spin columns using pre-immune serum, anti-RNA poly-
merase II antibody, or anti-UL4 antibody. DNAs were eluted and
recovered, and PCR assays were carried out to amplify precipitated
target sequences. As shown in Fig. 3, RNA polymerase II as the
positive control was readily detected and associated with the EHV-
1 UL4 promoter. In contrast, antibody to the UL4 protein failed to
reveal an association of this EHV-1 protein with the UL4 promoter
or with the immediate-early, early TK, or late gK promoters
(Fig. 3). Similar ﬁndings were obtained at both early (6 h) and
late times (10 h and 16 h) after infection and indicate that the UL4
protein is not directly associated with viral DNA sequences and
suggest that the inhibition of EHV-1 gene expression by UL4P is
not mediated through its binding to promoter DNA sequences.
The UL4P directly interacts with TBP and RNA polymerase II
Whether the UL4 protein interacts with cellular transcription
factors to inhibit gene expression was examined as a possible
mechanism for decreased transcription. Initial experiments were
carried out with general transcription factors (GTFs) involved in
the assembly of the pre-initiation complex (PIC) at gene promoters
(Buratowski et al., 1989; Davison et al., 1983; Kornberg, 2007; Van
Dyke et al., 1988). The TFIID complex, which includes the TATA
Table 1
EHV-1 glycoprotein 2 transcripta.
Act Db 3 6 9 12 15 18
Wild-type infected RK-13 cells
Exp 1
0.74
0.73 0.64 0.73 0.66 0.76
Exp 2
0.99
0.98 0.98 0.99 0.99 0.94
Exp 3
1.00
1.00 0.99 1.00 1.00 0.97
Avg 0.91 0.90 0.87 0.90 0.88 0.89
ΔUL4 infected RK 13 cells
Exp 1 0.89 0.84 0.71 0.63 0.71 0.21
Exp 2 0.99 0.99 0.99 0.99 0.98 0.99
Exp 3 1.00 1.00 1.00 1.00 0.99 1.00
Avg 0.96 0.94 0.90 0.87 0.90 0.73
Exp, experiment; Avg, average.
a Transcript levels normalized to 28S rRNA.
b Times post-Actinomycin D treatment (h) added 12 h post-infection.
IE TK IR4 UL5
Free 1 42 5 63 7
probes
1 42 5 63 7 8
1 42 5 631 42 5 63
Fig. 2. Electromobility shift assays examining whether the UL4 protein possesses the ability to bind EHV-1 promoters. (A) Immediate-early (IE) promoter DNA (120/þ73);
(B) thymidine kinase (TK) promoter DNA (193/þ133); (C) IR4 promoter DNA (267/þ17); and (D) UL5 promoter DNA (199/þ20) were radiolabeled and incubated with
various amounts of the protein under standard conditions described in “Materials and Methods” section. The amount of GST and GST–IR2P used in this experiment was
100 ng. Triangles: increasing amounts of the GST-UL4P added at 1 (100 ng), 3 (300 ng), 6 (600 ng). Control serum (con), IR2P-speciﬁc monoclonal antibody (A1.4;
Caughman et al., 1995), and IEP TAD-speciﬁc polyclonal antibody (α-TAD; Kim et al., 2011) were used. The position of complexes formed by the IR2P is indicated with arrows.
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box-binding protein (TBP), plays a critical role in initiating PIC
assembly and transcription and is a target for a number of viral
proteins including the E1A protein of adenovirus (Geisberg et al.,
1995), the ICP4 protein of herpes simplex virus 1 (Lester and
DeLuca, 2011), as well as the EHV-1 IE, IR2, EICP0, and UL5
proteins (Albrecht et al., 2004; Kim et al., 2003, 2006, 2011).
Direct protein–protein interactions were assessed using in vitro
GST-pulldown assays with the GST–UL4 fusion protein and pur-
iﬁed cellular transcription factors TFIIA, TFIIB, TBP and RNA
polymerase II (Pol II). Again, the GST protein and GST–IR2 fusion
protein were used as negative and positive controls, respectively.
Expectedly, the GST protein alone did not interact with any of the
cellular GTFs (Fig. 4, lanes A3 and B3). When puriﬁed TBP was
incubated with GST–IR2, a direct interaction was observed (Fig. 4A,
lane 4). TBP was also found to bind to the GST–UL4 fusion protein
(Fig. 4A, lane 5). Similar results were obtained when the GST–IR2
and GST–UL4 fusion proteins were incubated with puriﬁed sam-
ples of the carboxy-terminal domain (CTD) of Pol II, as shown in
Fig. 4B, lanes 4 and 5. However, no interaction was observed
between GST–UL4 and TFIIA, TFIIB, or the EHV-1 IEP (Fig. 5). These
ﬁndings indicate that the UL4 protein directly interacts with TBP
and the CTD of Pol II, observations that suggest that the UL4
protein may prevent the assembly of a pre-initiation complex at
viral promoters to inhibit gene expression.
The UL4 protein partners with TBP and pol II during EHV-1 infection
It was demonstrated that the UL4P directly interacts with TBP
and RNA polymerase II (Pol II) in vitro through GST-pulldown
assays (Fig. 4). However, as this is an artiﬁcial system to examine
protein–protein interactions, we next addressed whether this
interaction occurred during viral infection. HeLa cells were mock
infected or infected with the wild-type RacL11 strain of EHV-1.
Co-immunoprecipitation assays were performed using the UL4-
speciﬁc OC95 antibody (Charvat et al., 2011) or a non-related
antibody to EHV-1 glycoprotein D (gD). The immunoprecipitated
complexes were subjected to SDS-PAGE and western blot analysis
using antibodies speciﬁc for TBP or Pol II (Fig. 6). Immunopreci-
pitation with the anti-UL4P antibody of mock infected cell extracts
yielded no interaction with either TBP or Pol II (Fig. 6A, lane 2;
Fig. 6B, lane 2, respectively). Additionally, assays that included the
anti-gD antibody produced no interactions of the UL4 protein with
TBP or Pol II from HeLa cells infected with EHV-1 (Fig. 6A, lane 3;
Fig. 6B, lane 3, respectively). However, when the anti-UL4P anti-
body was used to immunoprecipitate protein complexes from
EHV-1 infected cells, interactions of the UL4 protein were observed
with both TBP and Pol II (Fig. 6A, lane 4; Fig. 6B, lane 4,
respectively).
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Fig. 3. ChIP assays to assess if the UL4 protein was bound to EHV-1 promoters in
infected HeLa cells at 16 h post infection. Assays were carried out as described in
the “Materials and Methods” section. Similar results were obtained at early (6 h)
and 10 h post infection. PCR results were analyzed for the UL4, IE, TK, and gK
promoters. In all assays, PCR bands obtained from DNA samples immunoprecipi-
tated with anti-UL4 antibody did not differ signiﬁcantly from those obtained with
the pre-immune serum.
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Fig. 4. GST-pulldown assays were completed to determine whether the UL4
protein directly interacts with general transcription factors. Puriﬁed GST, GST–
IR2, or GST–UL4 fusion proteins were incubated with GST-Bind resin beads for 1.5 h
before being combined with (A) TATA box-binding protein (TBP) or (B) RNA
polymerase II carboxy-terminal domain (Pol II CTD) for an additional 1.5 h
incubation. Captured proteins were eluted and resolved by SDS-PAGE and western
blot using TBP or Pol II CTD speciﬁc antibodies. MW, molecular weight marker.
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TFIIA55
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TFIIB36
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Fig. 5. GST-pulldown assays were completed to determine whether the UL4
protein directly interacts with general transcription factor TFIIA or TFIIB or the
EHV-1 IE protein. Puriﬁed GST (negative control), GST–TAD (positive control),
GST-IE (positive control) or GST–UL4 fusion proteins were incubated with GST-Bind
resin beads for 1.5 h before being combined with (A) TFIIA, (B) TFIIB, or (C) EHV-1
IE. Captured proteins were eluted and resolved by SDS-PAGE and western blot
using anti-TFIIA antibody, anti-TFIIB antibody, or anti-IE speciﬁc antibody. MW,
molecular weight marker. Details are in the “Materials and Methods” section.
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To conﬁrm these interactions of the UL4 protein with these two
cell factors essential for transcription, reverse immunoprecipita-
tion assays using antibody to TBP and antibody to Pol II CTD were
carried out. Control reactions employed pre-immune serum or
anti EHV-1 gD antibody. Precipitates were then probed with
pre-immune serum or anti-UL4P antibody. As shown in Fig. 7A,
precipitates obtained from EHV-1 infected cells with anti-TBP
antibody revealed the presence of the UL4 protein. In contrast
negative control precipitates of mock-infected cells or precipitates
obtained by use of anti-gD antibody as the primary antibody failed
to reveal the UL4 protein. Similarly, reverse precipitation assays
using anti-Pol II CTD antibody as the primary antibody conﬁrmed
the interaction of the UL4 protein with Pol II CTD during EHV-1
infection (Fig. 7B). The interaction of the UL4 protein with these
cellular factors was demonstrated at both early (6 h) and late
times (10 h and 16 h) after infection. Overall, ﬁndings from GST-
pulldown assays and both series of immunoprecipitation analyses
indicate that the interaction of the UL4 protein with the TBP and
Pol II occurs during viral infection.
Late gene expression is augmented in the absence of the UL4 protein
Our previous work (Charvat et al. 2011) and ﬁndings in Fig. 1
and Table 1 indicate that promoters representative of all three
EHV-1 gene classes were inhibited by the expression of the UL4
protein. However, the effect of the UL4 protein on global viral gene
expression was unknown. Therefore, the effect of the UL4 protein
on the expression of all 78 EHV-1 genes was assessed via
microarray analysis using cells that were either mock infected or
infected with wild-type EHV-1 or ΔUL4 EHV-1. It was hypothe-
sized that the greatest effect of UL4 protein expression would be
evident for the regulatory genes of EHV-1. Unexpectedly, it was
observed that the genes with the most enhanced expression in the
absence of the UL4 protein were those of the late class responsible
for mature virus particle assembly and maturation (Table 2A). The
included genes encode tegument proteins, capsid proteins, pro-
teins involved in cleavage and packaging of nascent genomes, and
glycoproteins. The only regulatory gene with signiﬁcantly
increased expression in the absence of the UL4 protein was the
late ETIF gene that encodes a protein that localizes within the
tegument and is necessary for secondary envelopment and egress
of viral particles (von Einem et al., 2006). The remaining regula-
tory genes of EHV-1 were considered to be unaffected in the
absence of the UL4 protein (Table 2B). As expected, no UL4 gene
expression was observed in the ΔUL4 EHV-1 infected cells. These
data suggest that during lytic infection, one role of the UL4 protein
is to regulate the expression of late genes.
Viral DNA synthesis is not retarded in cells infected with ΔUL4 EHV-1
The microarray data indicated that the genes most affected in
the absence of UL4 were those of the late class responsible for
assembly and maturation of viral particles. However, these
changes in viral gene expression did not signiﬁcantly affect virus
replication as the ΔUL4 EHV-1 and wild type EHV-1 replicated
with similar kinetics during a 24-h time course (Fig. 8A). Extensive
quantitative PCR analyses revealed that viral DNA synthesis was
not retarded in the absence of the UL4 protein, and cells infected
with wild type andΔUL4 EHV-1 produced similar amounts of viral
DNA by 24 h post infection (Fig. 8B).
Discussion
It was reported previously that transient expression of the EHV-1
UL4 protein inhibited expression from reporter genes that were under
the control of a variety of promoters (Charvat et al., 2011). Further-
more, in the absence of the UL4 protein during EHV-1 lytic infection,
expression of representative transcripts of all three gene classes was
increased. These observations suggested that the UL4 protein plays a
role in regulating gene expression, but no insight into the mechanism
of inhibition was provided. In this report, we demonstrate that
expression of the UL4 protein is associated with a decrease in the
level of reporter gene transcripts (Fig. 1). However, the reduced
transcript levels were not a result of increased mRNA instability or
turnover (Table 1). Taken together, these observations indicate that the
UL4 protein-mediated inhibition of gene expression occurs at the level
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Fig. 6. Co-immunoprecipitation assays with anti-UL4 protein antibody demon-
strating that the UL4 protein interacts with cellular transcription factors during
EHV-1 lytic infection. HeLa cells were infected with wild-type EHV-1 (MOI¼10),
and cell lysates were collected at 10 h post-infection. UL4 protein speciﬁc antibody
and non-speciﬁc anti-glycoprotein D (gD) antibody were conjugated to Protein-A
agarose beads and were then incubated with cellular lysates from mock-infected or
EHV-1-infected cells. Immunoprecipitated proteins were resolved by SDS-PAGE and
immunoblotted for either (A) TBP or (B) Pol II CTD. MW, molecular weight marker.
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Fig. 7. Co-immunoprecipitation assays with antibodies speciﬁc for TBP and Pol II
CTD demonstrating that the UL4 protein interacts with cellular transcription factors
during EHV-1 lytic infection. HeLa cells were infected with wild-type EHV-1
(MOI¼10), and cell lysates were collected at 6, 10, and 16 h post-infection.
(A) Anti-TBP antibody or (B) anti-Pol II CTD antibody and non-speciﬁc anti-
glycoprotein D (gD) antibody as a negative control were conjugated to Protein-A
agarose beads and were incubated with cellular lysates from mock-infected or
EHV-1 infected cells. Immunoprecipitated proteins were resolved by SDS-PAGE and
immunoblotted with anti-UL4 protein antibody. MW, molecular weight marker.
Results from 16 hpi are shown; similar results were obtained at 6 and 10 h post-
infection.
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of transcription. However, the UL4 protein does not inhibit gene
expression by binding to viral promoters as demonstrated by
gel retardation and ChIP assays, which is in contrast to that demon-
strated for the EHV-1 IR2 negative regulatory protein (Kim et al., 2006,
2011).
Protein–protein interactions with cellular transcription factors
play a role in inhibiting viral gene expression in a number of viral
systems. The human T-cell leukemia virus encodes a bZIP factor
that interacts with transcription factor CREB-2 to regulate viral
gene expression (Gaudray et al., 2002). Protein interactions
between the simian virus 40 (SV40) T antigen and AP-2 prevent
AP-2 from binding to DNA to activate viral gene transcription
(Mitchell et al., 1987). During infection with high-risk human
papillomaviruses, the viral E8\widehatE2C protein mediates
repression of viral gene expression by interacting with cellular
corepressor molecules, nuclear receptor corepressor 1 (NCoR1),
and the chromodomain helicase DNA binding domain 6 protein
(CHD6) (Ammermann et al., 2008; Fertey et al., 2010; Powell
et al., 2010). Therefore, it was hypothesized that the UL4 protein
mediated its inhibitory activity during the process of transcrip-
tion, presumably at the stage of pre-initiation complex (PIC)
assembly and recruitment of the RNA polymerase. Indeed,
protein–protein interaction assays revealed that the UL4 protein
could directly bind to puriﬁed TATA box-binding protein (TBP)
and the carboxy-terminal domain (CTD) of Pol II (Fig. 4). Addi-
tionally, a series of co-immunoprecipitation analyses conﬁrmed
that the UL4 protein interacted with these two cellular factors in
EHV-1 infected cells (Figs. 6 and 7). Additional experiments
showed that the UL4 protein did not directly associate with
general transcription factors TFIIA or TFIIB or with the sole
EHV-1 immediate early regulatory protein (Fig. 5). The possibility
that the UL4 protein could prevent TBP translocation into the
nucleus, thus blocking the critical initiating step in PIC assembly
was not substantiated by ongoing immunoﬂuorescence assays to
monitor TBP localization in the presence and absence of UL4
protein expression (data not shown). It remains unclear whether
the direct interaction of the UL4 protein with TBP and Pol II
diminishes their ability to interact with DNA. This question and
the identiﬁcation of domains within the UL4 protein responsible
for its interaction with general transcription factors are the focus
of future studies.
It has been well documented that the phosphorylation state of the
CTD of Pol II is intimately involved in the progression of transcription
from initiation and elongation to termination (Buratowski et al., 1989;
Hirose and Ohkuma, 2007; Kobor and Greenblatt, 2002). A potential
mechanism for the UL4 protein-mediated inhibition of gene
Table 2A
Ehv-1 genes display enhanced expression in the absence of the Ul4 genea.
Gene Exp 1 Exp 2 Exp 3 Avgb SEMc Name Functiond HSV
ORF 16 0.92 3.01 2.63 2.82 0.190 UL16 gC UL44
ORF 71 1.02 2.23 2.59 2.41 0.180 US4 gp2 none
ORF 57 1.17 2.41 2.40 2.40 0.005 UL57 Helicase/primase UL5
ORF 72 1.25 2.33 2.28 2.31 0.025 US5 gD US6
ORF 54 1.15 2.14 2.34 2.24 0.100 UL54 Helicase/primase UL8
ORF 53 1.05 2.33 2.09 2.21 0.120 UL53 Ori-binding protein UL9
ORF 73 1.38 1.98 2.37 2.17 0.195 US6 gI US7
ORF 40 1.46 1.86 2.14 2.00 0.140 UL40 Tegument UL21
ORF 3 0.75 1.75 2.23 1.99 0.240 UL3 Tegument, conserved in DIP none
ORF 15 1.47 1.86 2.10 1.98 0.120 UL15 Membrane UL45
ORF 19 1.23 1.78 2.16 1.97 0.190 UL19 VHS UL41
ORF 58 1.40 1.75 2.02 1.88 0.135 UL58 Virion UL4
ORF 33 1.65 1.73 1.98 1.86 0.125 UL33 gB UL27
ORF 36 1.62 1.57 2.12 1.84 0.275 UL36 Capsid UL25
ORF 41 1.50 1.57 2.10 1.83 0.265 UL41 Virion UL20
ORF 52 1.31 1.73 1.93 1.83 0.100 UL52 gM UL10
ORF 60 1.70 1.72 1.93 1.83 0.105 UL60 Colocalizes w. ICP22 UL3
ORF 13 1.38 1.78 1.86 1.82 0.040 UL13 VP13/14 tegument UL47
ORF 6 1.58 1.51 1.97 1.74 0.230 UL6 gK UL53
ORF 56 1.29 1.61 1.87 1.74 0.130 UL56 Portal protein UL6
ORF 62 1.44 1.68 1.76 1.72 0.040 UL62 gL UL1
ORF 61 1.59 1.75 1.68 1.71 0.035 UL61 Uracil–DNA glycosylase UL2
ORF 12 1.39 1.60 1.83 1.71 0.115 UL12 ETIF UL48
ORF 9 1.28 1.54 1.85 1.70 0.155 UL9 dUTPase UL50
ORF 35 1.64 1.58 1.82 1.70 0.120 UL35 Protease UL26
ORF 11 1.72 1.73 1.66 1.70 0.035 UL11 VP22 tegument UL49
ORF 42 1.88 1.62 1.75 1.68 0.065 UL42 VP5 capsid UL19
ORF 10 1.39 1.93 1.44 1.68 0.245 UL10 Membrane UL49a
ORF 55 1.38 1.65 1.70 1.67 0.025 UL55 Tegument/virion UL7
ORF 14 1.68 1.68 1.66 1.67 0.010 UL14 Tegument UL46
ORF 43 1.41 1.60 1.74 1.67 0.070 UL43 VP23 capsid UL18
ORF 70 1.69 1.61 1.72 1.67 0.055 US3 gG US4
ORF 68 1.70 1.65 1.67 1.66 0.010 US1 Virion US2
ORF 37 1.27 1.54 1.74 1.64 0.100 UL37 Membrane UL24
ORF 47-44 1.27 1.46 1.80 1.63 0.170 Packaging UL15
ORF 23 1.46 1.49 1.77 1.63 0.140 UL23 ICP32 UL37
ORF 22 1.39 1.48 1.77 1.63 0.145 UL22 VP19C capsid UL38
ORF 35.5 1.68 1.52 1.71 1.62 0.095 UL35.5 ICP35 capsid assembly UL26.5
ORF 59 1.77 1.49 1.74 1.61 0.125 UL59 ? VZV ORF 57 None
ORF 30 1.31 1.39 1.81 1.60 0.210 UL30 DNA pol UL30
a Fold increase ΔUL4 EHV-1 vs. wild-type EHV-1. Data are from three independent experiments (Exp). Exp 1 MOI¼5; Exp 2 & 3 MOI¼10.
b Average fold increase for Exps 2 & 3.
c Standard error from mean Exps 2 & 3.
d Function based on sequence analysis (Telford et al., 1992).
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expression may involve dysregulation of the dynamic process of CTD
phosphorylation. The direct interaction of the UL4 protein with the
CTD may prevent the association between the kinases and/or phos-
phatases that maintain the appropriate levels of phosphorylation to
switch between initiation and elongation or elongation and termina-
tion. Likewise, the inhibitory activity may involve binding of the UL4
protein such that it directly eclipses the serines in the heptapeptide
repeats that are the targets of phosphorylation (Hengartner et al.,
1998; Komarnitsky et al., 2000; Ni et al., 2004). Whether the UL4
protein alters the state of CTD phosphorylation is an interesting
avenue of investigation and would represent a novel mechanism for
EHV-1 gene regulation.
That the majority of the EHV-1 genes with enhanced expres-
sion in the absence of the UL4 protein were those of the late gene
class responsible for assembly and maturation of infectious viral
particles was unexpected (Tables 2A and 2B). Thus, during lytic
infection, expression of the UL4 protein may prevent the late
genes from being transcribed before DNA replication has com-
pleted. This could limit the exhaustion of the nucleotide pool and
prevent translation of structural proteins that might assemble
capsids before signiﬁcant numbers of daughter genomes can be
replicated, which would diminish the assembly of non-infectious
empty particles. Additionally, the reduction of late gene
expression may facilitate efﬁcient DNA replication, due to the
fact that the incoming viral genome would serve as the template
for DNA replication as opposed to a template for late gene
transcription. Despite these considerations, extensive quantita-
tive PCR analyses clearly revealed that viral DNA synthesis is not
retarded in the absence of the UL4 protein (Fig. 8B). It is possible
that the UL4 protein preferentially regulates late genes by
preventing the association of the IE and UL5 proteins with
general transcription factors, such as TBP, that were demon-
strated to be critical for maximal EHV-1 late gene expression
(Albrecht et al., 2004; Zhao et al., 1995). Additional studies are
focused on determining if the UL4 protein competes with the IE
and UL5 proteins for binding to TBP.
Overall, these ﬁndings further demonstrate the inhibitory
activity of the UL4 protein and suggest a mechanism by which
the UL4 protein affects viral gene expression, namely its direct
interactions with two cellular proteins essential for transcrip-
tion. These interactions may be important for the inhibition of
late gene expression as well as for efﬁcient viral DNA replica-
tion. Future studies will address how the interactions between
the UL4 protein and the transcription machinery contribute
to the inhibition of EHV-1 gene expression and efﬁcient viral
replication.
Table 2B
Ehv-1 genes display enhanced expression in the absence of the Ul4 genea.
Gene Exp 1 Exp 2 Exp 3 Ave SEM Name Functionb HSV
ORF 38 1.54 1.45 1.76 1.60 0.155 UL38 Thymidine kinase UL23
IR 3 1.52 1.17 2.03 1.60 0.430 IR3 Micro RNA None
ORF 39 1.67 1.41 1.78 1.60 0.185 UL39 gH UL22
ORF 18 1.89 1.54 1.61 1.58 0.035 UL18 DNA process UL42
ORF 45 1.59 1.42 1.73 1.57 0.155 UL45 Tegument req. cleavage/packaging UL17
ORF 74 1.33 1.45 1.59 1.52 0.070 US7 gE US8
ORF 17 1.10 1.61 1.43 1.52 0.090 UL17 Membrane UL43
ORF 46 1.93 1.38 1.63 1.50 0.125 UL46 Capsid-assoc. req. for cleavage/packaging UL16
ORF 49 1.77 1.35 1.66 1.50 0.155 UL49 Tyr kinase UL13
ORF 75 1.96 1.40 1.60 1.50 0.100 US8 “10K” None
ORF 34 1.96 1.45 1.54 1.49 0.045 UL34 ? None
ORF 29 1.61 1.37 1.61 1.49 0.120 UL29 Req. for envelopment UL31
ORF 50 1.69 1.38 1.59 1.49 0.105 UL50 Alkaline DNase UL12
ORF 28 1.56 1.35 1.59 1.47 0.120 UL28 Cleavage/packaging UL32
ORF 8 1.34 1.32 1.61 1.47 0.145 UL8 Tegument UL51
ORF 27 1.29 1.27 1.64 1.46 0.185 UL27 Packaging UL33
ORF 24 1.53 1.37 1.54 1.46 0.085 UL24 ICP1/2 tegument UL36
ORF 69 1.23 1.44 1.45 1.45 0.005 US2 Protein kinase US3
ORF 25 2.18 1.27 1.61 1.44 0.170 UL25 Capsid UL35
ORF 20 1.93 1.24 1.64 1.44 0.200 UL20 RR2 UL40
ORF 7 1.19 1.27 1.56 1.42 0.145 UL7 Helicase/primase UL52
ORF 26 1.66 1.30 1.52 1.41 0.110 UL26 Membrane UL34
ORF 5 1.32 1.31 1.46 1.39 0.075 UL50 EICP27 UL54
ORF 51 2.13 1.21 1.56 1.38 0.175 UL51 Virion and envelopment UL11
ORF 31 1.57 1.36 1.40 1.38 0.020 UL31 ICP8 ss DNA-binding protein UL29
ORF 48 1.22 1.17 1.58 1.38 0.205 UL48 Tegument UL14
ORF 21 1.31 1.24 1.47 1.36 0.115 UL21 RR1 UL39
ORF 67 1.91 1.35 1.36 1.36 0.005 IR6 Virion, forms ﬁlaments None
IR4/UL3 1.31 1.18 1.45 1.32 0.135 Hybrid None
ORF 32 1.09 1.19 1.30 1.24 0.055 UL32 Cleavage/packaging UL28
ORF 64.1 0.74 0.95 1.50 1.23 0.275 IR1 IE ICP4
ORF 76 0.94 1.14 1.29 1.22 0.075 US9 Tegument US9
ORF 63 1.35 1.00 1.36 1.18 0.180 UL63 EICP0 IE 110
ORF 65 1.13 1.00 1.25 1.13 0.125 IR4 EICP22 US1
ORF 1c 1.06 0.69 1.50 1.10 0.405 UL1 MHC-1 downregulation UL56
Actin 0.80 1.01 1.00 1.00 0.005
GAPDH 1.00 1.00 1.00 1.00 0.000
ORF4d 0.10 0.17 0.38 0.27 0.105 UL4 Inhibitory protein, req. for DIP generation UL55
Ave: average fold increase for Exps 2 & 3, SEM: standard error from mean Exps 2 & 3.
a Fold increase ΔUL4 EHV-1 vs. wild-type EHV-1. Data are from three independent experiments (Exp). Exp 1 MOI¼5; Exp 2 & 3 MOI¼10.
b Function based on sequence analysis (Telford et al., 1992).
c ORF1 deleted in wild-type EHV-1 and ΔUL4 EHV-1.
d ORF4 deleted in ΔUL4 EHV-1 but present in wild-type EHV-1.
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Materials and methods
Cell culture and viruses
Mouse ﬁbroblast L–M, rabbit kidney RK13, and human HeLa
cells were grown in Dulbecco's minimum essential medium
(DMEM) supplemented with 5% fetal bovine serum at 37 1C in a
5% CO2 incubator. Wild-type, ΔUL4, and ΔUL4Res EHV-1 of the
pathogenic RacL11 strain background were used for these studies
(Charvat et al., 2012).
Plasmids and transfection procedure
The luciferase reporter plasmids, the effector gene expression
plasmids, and the GST fusion protein plasmids used in the
transient transfection assays were generated elsewhere (Bowles
et al., 2000; Charvat et al., 2011; Smith et al., 1992). RK13 cells
were transfected using lipofectin (Invitrogen, Carlsbad, CA) and
Opti-MEM medium (Gibco, BRL, Carlsbad, CA) as described pre-
viously (Ahn et al., 2007). One pmol of reporter plasmid and
0.5 pmol of effector plasmid were employed in most assays.
Transfection efﬁciencies of 70% or greater were routinely obtained.
Luciferase and northern blot analysis
Two groups of RK13 cells were co-transfected with gK-Luc and
either the EICP0 or UL4 protein expression plasmids. For one group of
cells, luciferase activity was determined 48 h post-transfection utiliz-
ing the luciferase activity kit (Promega, Madison, WI) and the
POLARstar OPTIMA plate reader (BMG LABTECH Inc., Cary, NC) per
manufacturer's instructions (Ahn et al., 2007). For the other group of
cells, total RNA was isolated at 4 h post-transfection using the RNA-
Bee RNA isolation reagent (AMS Biotechnology (Europe) Ltd., Abing-
don, UK). RNA samples were separated on a 6% denaturing urea-
polyacrylamide gel and transferred onto a positively-charged nylon
membrane (Ambion, Austin, TX) using a semi-dry electroblotter (Bio-
Rad Laboratories). Immobilized RNA was hybridized with a probe
speciﬁc for the luciferase transcript (5′-GGTGTTGGAGCAAGATGGAT-
3′). RNA levels were determined by densitometric measurement of
the radiolabeled bands after exposure to a phosphor screen and
scanning with the molecular imager FX system.
mRNA half-life
Rabbit kidney cells were infected with either wild-type EHV-1
or ΔUL4 EHV-1 at an MOI of 5. Twelve hours post-infection, the
normal growth medium was replaced with growth medium
supplemented with 1 μM Actinomycin D. Every 3 h, total RNA
samples were collected for a total of 18 h. cDNA was synthesized
from the RNA samples using the iScript™ cDNA Synthesis Kit per
the manufacturer's speciﬁcations (Bio-Rad Laboratories). Tran-
script levels were determined by quantitative real-time PCR
analysis using the iQ™ SYBRs Green Supermix (Bio-Rad Labora-
tories). The EHV-1 glycoprotein 2 (gp2, gene EUs4) transcript was
detected with forward primer 5′-TACAACAACTGAGACTAC-3′ and
reverse primer 5′-GGAGAACTGCTACTATTAG-3′, and the total
transcript levels were normalized to cellular 28S rRNA using
forward primer 5′-TATCATTGTGAAGCAGAA-3′ and reverse primer
5′-AACAACACATCATCAGTA-3′.
Electromobility shift assays
DNA binding assays were completed using IE, TK, IR4, and UL5
promoter DNA sequences along with GST, GST–IR2, or GST–UL4
fusion proteins. Promoter DNAs were radiolabeled with [α-32P]-
dATP and diluted in DNA-binding buffer (10 mM Tris–HCl [pH 7.5],
1 mM EDTA, 10 mM β-mercaptoethanol, 0.1% CHAPS, 100 mM
NaCl). Radiolabeled promoter DNAs were incubated with equiva-
lent amounts of puriﬁed GST fusion proteins for 20 min at room
temperature (Kim et al., 1995). DNA–protein complexes were
resolved on a 3.2% polyacrylamide gel and then dried onto What-
man chromatography paper (Whatman International Ltd., Maid-
stone, England). The chromatography paper was exposed to a
phosphor screen and scanned with the molecular imager FX
system.
Chromatin immunoprecipitation assays (ChIP)
HeLa cells were infected with EHV 1 RacL11 at a MOI of 10 and
harvested at 6, 10, 12, and 16 h after infection. The cells were
crosslinked with 1% formaldehyde for 10 min followed by adding
1 glycine for 5 min. After adding the Halt protease and phos-
phatase inhibitor cocktail (Pierce Biotechnology, Rockford, IL), the
cells were scrapped and collected. The chromatin preparation was
then processed according to the manufacturer's protocol (Pierce
Biotechnology). Lysis buffer was added and micrococcal nuclease
digestion was carried out for 15 min at 37 1C followed by
centrifugation at 9000g for 5 min. Pre-immune serum, anti-UL4
antibody (Charvat et al., 2011) or anti CTD of Pol II antibody
(Protein One, Bethesda, MD) was added in a spin column and
incubated overnight at 4 1C. After washing, the elution process and
DNA puriﬁcation were carried out according to the manufacturer's
protocol. PCR was performed to amplify the target DNA using
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Fig. 8. Quantitative PCR and virus titer were employed to examine the growth of UL4-
deleted EHV-1 as compared to the wild type EHV-1 RacL11. RK13 cells were infected at
MOI of 10, and the infected cells were harvested at 4, 6, 12 and 24 h post infection.
(A) Infectious virus titers were determined by plaque assays as described in the
“Materials and Methods” section. (B). DNA was isolated using DNA STAT-60 reagent or
DNeasys Blood & Tissue Kit. Viral DNA was measured by quantitative PCR analyses by
detecting the gp2 DNA sequence and normalizing to the levels of cellular GAPDH. Data
shown are from four independent assays, and details are in the “Material and Methods”
section.
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appropriate primers: EHV 1 UL4 gene was ampliﬁed by the
forward primers: 5′-CAT GGT ACC CCA ACG CAA ACA GTT GGC
ACC GTG-3′, and reverse primers 5′-CAT AGA TCT CAG GCT GGG
AAT TTG CTC GAC TGA AG-3′. The EHV 1 IE gene was ampliﬁed by
the forward primers: 5′-ACG ACG ATG AGA TGG AGA TG-3′, and
reverse primers 5′-ACA GCG ATA CCG AGA CCT G-3′. The EHV 1 TK
gene was ampliﬁed by the forward primers: 5′-GAG CAC GAC TGG
ACG AGT TA-3′, and reverse primers 5′-GTC CGC TTC AAA GAG AGT
CC-3′. The EHV 1 gK gene was ampliﬁed by the forward primers:
5′-AAA GGT CCT GCT TAG AGC CA-3′, and reverse primers 5′-ACG
AGT TCT TAT CGC CGA CT-3′. PCR products were analyzed in a
BioRad XR imaging system. Pre-immune serum was employed as
the negative control.
GST-pulldown assays
In vitro protein–protein interaction assays were described
previously (Albrecht et al., 2004). Brieﬂy, 2 mg of puriﬁed GST,
GST–IR2, or GST–UL4 protein was combined with 40 mL of a 50%
mix of GST-Bind resin beads (Novagen, Madison, WI) in 650 mL
NETN buffer (100 mM NaCl, 1 mM EDTA, 20 mM Tris–HCl [pH 8.0],
0.5% NP-40) and incubated at room temperature for 1.5 h. One
microgram of puriﬁed transcription factors TATA box-binding
protein (TBP), Pol II CTD, TFIIA, or TFIIB (Protein One, Bethesda,
MD) were added to the samples and incubated for an additional
1.5 h. The samples were centrifuged and washed ﬁve times with
NETN buffer. Precipitated proteins were resolved by SDS-PAGE on
10% polyacrylamide gels and transferred to nitrocellulose mem-
branes. Transcription factor protein complexes were detected with
speciﬁc antibodies to TBP, Pol II CTD, TFIIA or TFIIB (Protein One).
Antibody to the EHV-1 IE protein was described previously (Kim
et al., 2003).
Co-immunoprecipitation assays
Human HeLa cells were infected with wild-type RacL11 EHV-1
(MOI¼10) and cellular lysates were prepared at 6, 10 and 16 h
post-infection. The samples were diluted with a Tris–saline solu-
tion (10 mM Tris–HCl [pH 8.0] and 14 mM NaCl) and pre-cleared
by mixing with 30 mL of a 50% mix of Protein-A agarose beads
(Sigma, St. Louis, MO) for 2 h at room temperature. At the same
time, 10 mL of the UL4 protein-speciﬁc antibody (Charvat et al.,
2011) or a non-related anti-glycoprotein D (gD) speciﬁc antibody
were complexed with a separate 30 mL of a 50% mix of Protein-A
agarose beads. The beads were pelleted by centrifugation, and the
pre-cleared samples were added to the antibody-bound beads and
incubated for 2 h at room temperature. The beads were washed
ﬁve times with 500 mL of the Tris–saline solution, and after the
ﬁnal wash, the beads were pelleted. SDS sample buffer was added,
and the samples were boiled for 5 min before being resolved on
10% polyacrylamide gels. The precipitated protein complexes were
detected with either the TBP or Pol II CTD speciﬁc antibodies
(Protein One). Reverse immunoprecipitation assays using antibody
to TBP and antibody to Pol II CTD were carried out by a similar
procedure. Control reactions employed pre-immune serum or anti
EHV-1 gD antibody. Precipitates were then probed with pre-
immune serum or anti-UL4P antibody. The input proteins, TBP
and Pol II CTD, were obtained from Protein One.
Microarray analysis
RK13 cells were infected with wild-type or ΔUL4 EHV-1
(MOI¼10) for 18 h before total RNA was isolated using the RNA-
Bee reagent. Double-stranded cDNA was synthesized using the
SuperScripts Double-Stranded cDNA Synthesis Kit and Oligo
(dT)12–18 Primer (Invitrogen) following the manufacturer's
protocol. The cDNA was ﬂuorescently labeled with the Label ITs
mArray™ Cy™3/Cy™5 Labeling Kit (Mirus, Madison, WI) as per
manufacturer's instructions and puriﬁed using the MinElutes PCR
Puriﬁcation Kit (QIAGEN, Germantown, MD). Labeled cDNA was
hybridized to the EHV-1 CustomArray 42K microarray following
the manufacturer's procedure (CustomArray Inc., Bothell, WA). All
78 EHV-1 genes are represented on the microarray. Each gene is
represented by 5–10 unique oligonucleotide sequences, each of
which is present in triplicate. The microarray also contains host
cellular genes GAPDH, GAPDG, and actin. The microarray was
scanned using the GenePix 4000B Microarray Scanner (Molecular
Devices, LLC, Sunnyvale, CA).
Quantitation of viral genomic DNA and infectious titers
Rabbit kidney cells (RK13) were infected with wild-type
(RacL11) or ΔUL4 EHV-1 at a MOI of 10. At 4, 6, 8, 12, and 24 h
post infection, infected cells were pelleted and freeze and thaw for
three times for virus titration by plaque assay on RK13 monolayers
(Perdue et al., 1974). For quantitative real-time PCR to measure
viral DNA, DNA was extracted from infected cell pellets using the
DNeasys Blood &Tissue Kit (QIAGEN, Valencia, CA) following the
manufacture's protocol. Quantitative PCR assays were performed
using the iScript™ One-Step RT-PCR Kit SYBRs Green and iQ™
SYBRs Green supermix (Bio-Rad Laboratories, Hercules CA) and
primers for cellular GAPDH (forward: 5′-TGCCCCCATGTTTGTGATG-
3′ reverse: 5′-TGTGGTCATGAGCCCTTC-3′) and the EHV-1 glyco-
protein K (gK) gene (forward: 5′-AAAGGTCCTGCTTAGAGCCA-3′
reverse: 5′-ACGAGTTCTTATCGCCGACT-3′), and the EHV-1 gp2
gene primers (forward: 5′-TACAACAACTGAGACTAC-3′ reverse:
5′-GGAGAACTGCTACTATTAG-3′). Statistical analysis for the infec-
tious titer results was completed using the mean of log-
transformed data and a two way Student T test, and one way T
test for the quantitation of viral genomic DNA.
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